37821
document
Can HMG Co-A reductase inhibitors ( " statins " ) slow the progression of age-related macular degeneration ? The age-related maculopathy statin study ( ARMSS ) . Age-related macular degeneration ( AMD ) is responsible for the majority of visual impairment in the Western world . The role of cholesterol-lowering medications , HMG Co-A reductase inhibitors or statins , in reducing the risk of AMD or of delaying its progression has not been fully investigated . A 3-year prospective randomized controlled trial of 40 mg simvastatin per day compared to placebo in subjects at high risk of AMD progression is described . This paper outlines the primary aims of the Age-Related Maculopathy Statin Study ( ARMSS ) , and the methodology involved . Standardized clinical grading of macular photographs and comparison of serial macular digital photographs , using the International grading scheme , form the basis for assessment of primary study outcomes . In addition , macular function is assessed at each visit with detailed psychophysical measurements of rod and cone function . Information collected in this study will assist in the assessment of the potential value of HMG Co-A reductase inhibitors ( statins ) in reducing the risk of AMD progression .
37822
Intervention_Pharmacological
HMG Co-A reductase inhibitors ( " statins " )
37823
Intervention_Pharmacological
HMG Co-A reductase inhibitors or statins
37824
Intervention_Pharmacological
40 mg simvastatin per day
37825
Intervention_Control
placebo
37826
Intervention_Pharmacological
HMG Co-A reductase inhibitors ( statins )
37827
Participant_Condition
age-related macular degeneration
37828
Participant_Condition
Age-related macular degeneration ( AMD )
37829
Participant_Condition
AMD